Advanced Cancer Therapeutics’ PFK-158 Featured in CEO/CFO Magazine; Announces MD Anderson and UT Health Science Center San Antonio Added as Clinical Trial Sites
Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, has been featured in the December 15, 2014 issue of CEO/CFO Magazine in which ACT President and CEO Randall B. Riggs discusses PFK-158, a first-in-man/first-in-class inhibitor of PFKFB3, an enzyme that controls glycolysis and that is overexpressed in most hematological and solid tumors.
Louisville, KY, December 17, 2014 --(PR.com)-- Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, has been featured in the December 15, 2014 issue of CEO/CFO Magazine in which ACT President and CEO Randall B. Riggs discusses PFK-158, a first-in-man/first-in-class inhibitor of PFKFB3, an enzyme that controls glycolysis and that is overexpressed in most hematological and solid tumors.
To read a full copy of the interview, please visit:
https://ceocfointerviews.com/interviews/AdvancedCancer14.htm
In the article, Mr. Riggs announces that two new clinical trial sites have been added: MD Anderson Cancer Center in Houston, Texas and the University of Texas Health Science Center in San Antonio, Texas. The two new sites are expected to begin enrolling patients starting in January 1, 2015.
PFK-158 human clinical trials began recruiting patients in May 2014 with the first clinical trial site located at the James Graham Brown Cancer Center, a part of KentuckyOne Health. Within weeks of opening the first clinical trial site, ACT was able to open the second clinical trial site, Georgetown University Medical Center in Washington, D.C., also in May 2014.
According to Mr. Riggs, “We were pleased to partner with MD Anderson and UT Health Science Center in San Antonio to expand the number of clinical trial sites for PFK-158. PFK-158 is a first-in-man, novel anti-cancer drug that prevents tumor cells from using glucose as a fuel source for tumor survival, growth and metastasis and is currently in a Phase 1 clinical study in the US.” In November 2014, PFK-158 was chosen by Informa and Kantar Health as one of the “2014 Top 10 Most Interesting Oncology Projects to Watch.”
PFK-158 is a small molecule that inactivates a novel cancer metabolism target never before examined in human clinical trials. Last spring, the U.S. Food and Drug Administration (FDA) approved Phase 1 dose escalation study that is evaluating the safety, tolerability and anti-tumor activity of PFK-158 in cancer patients with solid tumors such as prostate, lung, ovarian, melanoma, breast and pancreatic cancer.
PFK-158 is the first 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) inhibitor to undergo clinical trial testing in cancer patients. The target, PFKFB3, is activated by oncogenes and the low oxygen state in cancers, stimulates glucose metabolism and is required for the growth of cancer cells. PFK-158, which has been licensed by ACT from the James Graham Brown Cancer Center at the University of Louisville, inhibits the substrate binding domain of PFKFB3 causing a marked reduction in the glucose uptake and growth in multiple preclinical cancer models.
CEO/CFO Magazine is a weekly online publication featuring in-depth interviews with many of today's top corporate executives.
About Advanced Cancer Therapeutics (ACT):
ACT is a privately held company dedicated to advancing novel therapeutics for the prevention and treatment of cancer. ACT has successfully established a unique and innovative business model with the University of Louisville’s James Graham Brown Cancer Center (Brown Cancer Center) whereby ACT is able to obtain exclusive worldwide licenses to novel cancer therapeutics discovered at Brown Cancer Center under preset business terms. ACT then fast-tracks these discoveries, including the selection process for partnership, commercialization and manufacture, to the pharmaceutical industry, and ultimately to the patients who need them. Led by Dr. Donald M. Miller, the Brown Cancer Center employs more than 50 scientists focused on the discovery and advancement of breakthrough cancer therapeutics for patients suffering from cancer. For more information, please visit www.advancedcancertherapeutics.com.
To read a full copy of the interview, please visit:
https://ceocfointerviews.com/interviews/AdvancedCancer14.htm
In the article, Mr. Riggs announces that two new clinical trial sites have been added: MD Anderson Cancer Center in Houston, Texas and the University of Texas Health Science Center in San Antonio, Texas. The two new sites are expected to begin enrolling patients starting in January 1, 2015.
PFK-158 human clinical trials began recruiting patients in May 2014 with the first clinical trial site located at the James Graham Brown Cancer Center, a part of KentuckyOne Health. Within weeks of opening the first clinical trial site, ACT was able to open the second clinical trial site, Georgetown University Medical Center in Washington, D.C., also in May 2014.
According to Mr. Riggs, “We were pleased to partner with MD Anderson and UT Health Science Center in San Antonio to expand the number of clinical trial sites for PFK-158. PFK-158 is a first-in-man, novel anti-cancer drug that prevents tumor cells from using glucose as a fuel source for tumor survival, growth and metastasis and is currently in a Phase 1 clinical study in the US.” In November 2014, PFK-158 was chosen by Informa and Kantar Health as one of the “2014 Top 10 Most Interesting Oncology Projects to Watch.”
PFK-158 is a small molecule that inactivates a novel cancer metabolism target never before examined in human clinical trials. Last spring, the U.S. Food and Drug Administration (FDA) approved Phase 1 dose escalation study that is evaluating the safety, tolerability and anti-tumor activity of PFK-158 in cancer patients with solid tumors such as prostate, lung, ovarian, melanoma, breast and pancreatic cancer.
PFK-158 is the first 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) inhibitor to undergo clinical trial testing in cancer patients. The target, PFKFB3, is activated by oncogenes and the low oxygen state in cancers, stimulates glucose metabolism and is required for the growth of cancer cells. PFK-158, which has been licensed by ACT from the James Graham Brown Cancer Center at the University of Louisville, inhibits the substrate binding domain of PFKFB3 causing a marked reduction in the glucose uptake and growth in multiple preclinical cancer models.
CEO/CFO Magazine is a weekly online publication featuring in-depth interviews with many of today's top corporate executives.
About Advanced Cancer Therapeutics (ACT):
ACT is a privately held company dedicated to advancing novel therapeutics for the prevention and treatment of cancer. ACT has successfully established a unique and innovative business model with the University of Louisville’s James Graham Brown Cancer Center (Brown Cancer Center) whereby ACT is able to obtain exclusive worldwide licenses to novel cancer therapeutics discovered at Brown Cancer Center under preset business terms. ACT then fast-tracks these discoveries, including the selection process for partnership, commercialization and manufacture, to the pharmaceutical industry, and ultimately to the patients who need them. Led by Dr. Donald M. Miller, the Brown Cancer Center employs more than 50 scientists focused on the discovery and advancement of breakthrough cancer therapeutics for patients suffering from cancer. For more information, please visit www.advancedcancertherapeutics.com.
Contact
Advanced Cancer Therapeutics
Randall Riggs
502-589-6404
www.advancedcancertherapeutics.com
Randall Riggs
502-589-6404
www.advancedcancertherapeutics.com
Contact
Categories